Trombovazim

Selected form

-

Method of action: Adaptogenic, Adrenolytic, Adsorbing, Alpha-Adrenomimetic, Ample Deficiency, Analgesic, Analgetic, Androgenic, Angioprotective, Anorexigenic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trombovazim

Property	Description
Active ingredient	Proteolytic enzyme preparation (Subtilase)
Form	Capsules
Pharmacological class	Fibrinolytic agent (Direct Thrombolytic)
General purpose	Breakdown of intravascular blood clots (thrombus)
Origin	Derived (Exogenous bacterial proteinase)

Trombovazim is a specialized medicinal agent officially classified as a fibrinolytic agent, which corresponds to the B01AD section of the Anatomical Therapeutic Chemical (ATC) classification system. It functions as a unique direct thrombolytic drug, provided in capsules for oral administration. The primary general purpose of this enzyme preparation is to support vascular health by promoting the dissolution of existing intravascular clots or a thrombus.

The core component is a modified proteolytic enzyme preparation, specifically a derivative of the enzyme subtilase (subtilisin-like proteinase), which originates from exogenous bacterial proteinases. This active ingredient is structurally distinct because it is immobilized onto an inert polyethylene oxide polymer carrier. This unique composition is clinically recognized for protecting the protein-based enzyme from degradation in the digestive tract, allowing it to be effective as an oral drug.

The physiological action is that of a direct thrombolytic—the subtilase enzyme directly breaks down the fibrin mesh that forms the clot's structure, thereby accelerating clot lysis. This drug is often used to address issues related to chronic venous insufficiency by enhancing the clearance of existing obstructions. This antithrombotic effect is unique as it is delivered orally and operates without relying on the body's plasminogen activation system.

What side effects are possible with Trombovazim?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Trombovazim, based strictly on government regulatory documents.

Safety data categorizes documented adverse reactions primarily into Gastrointestinal disorders and Immune system disorders. Less frequently, Vascular/Musculoskeletal effects, described as a temporary sensation of arching or fullness in the lower limbs, have been noted

.

Official regulatory documents classify the frequency of adverse effects as follows:

Occasional / In Rare Cases: Dyspeptic phenomena, including nausea, vomiting, and a sense of heaviness in the stomach.
Possible: Allergic reactions (hypersensitivity).

The official labeling does not categorize any event as a "Serious Adverse Reaction."

Population-Specific Safety Constraints

The medicine is subject to specific constraints regarding patient populations and pre-existing conditions:

Pediatric Population: Safety and efficacy are not established for use in individuals under 18 years of age.
Pregnancy and Lactation: Use of the medicine is restricted during both pregnancy and the period of breastfeeding (lactation).
Pre-existing Conditions: The drug is restricted for individuals with known hypersensitivity to its components or those with an acute phase of a peptic ulcer or duodenal ulcer.

Caution is also advised in situations that may increase bleeding risk, such as the presence of esophageal varices, or in patients with a history of polyvalent allergy. These restrictions define the conditions under which the product's safety profile is considered acceptable.

Overdose and Emergency Response

The official regulatory documentation for the fibrinolytic agent Trombovazim capsules explicitly addresses the issue of overdose based on available clinical data. The prescribing information specifically states that no cases of overdose have been observed for the medicinal product. This unique regulatory finding forms the foundational constraint of the drug's official overdose profile.

In the absence of reported clinical cases, the official labeling does not define or list specific overdose manifestations, clinical symptoms, or specific laboratory findings that would indicate an excessive intake. Consequently, no physiological systems are identified in the official overdose section as being affected by an overdose scenario. The regulatory text also does not provide any specific dose-related factors or circumstances linked to an overdose risk.

Because there is no documented clinical data, the official regulatory instruction does not mandate specific immediate actions, describe procedural interventions, or detail first-aid measures required for overdose management. The label similarly does not define or detail any serious or life-threatening outcomes, nor does it specify official requirements for seeking urgent medical help in the event of an overdose. Furthermore, the regulatory documents do not include any population-specific considerations regarding increased overdose risk or severity.

Therapeutic Uses of Trombovazim

What Trombovazim treats: main uses and benefits

Trombovazim is a pharmaceutical preparation containing a complex of proteolytic enzymes, specifically subtilidins. It is utilized in clinical practice for its fibrinolytic, anti-inflammatory, and cardioprotective properties. The medication is designed to interact with the circulatory system to assist in the management of various cardiovascular and venous conditions.

Primary Clinical Applications

The therapeutic use of Trombovazim is centered on its ability to influence blood coagulation and vascular health. Its main applications include:

Chronic Venous Insufficiency: Trombovazim is frequently used to address the symptoms and underlying causes of chronic venous insufficiency. It helps reduce venous congestion, alleviate swelling (edema), and improve the overall tone of the venous walls.
Blood Clot Management: Due to its fibrinolytic activity, the medication assists in the gradual dissolution of blood clots (thrombi) without significantly disrupting the natural clotting process required for wound healing. This makes it a supportive option in treating conditions related to thrombosis.
Supportive Therapy in Cardiovascular Diseases: It may be used as part of a broader therapeutic approach for patients with ischemic heart disease or those recovering from acute cardiovascular events to improve microcirculation and reduce inflammatory responses in the vascular tissue.

Key Therapeutic Benefits

The benefits of Trombovazim are derived from its specific enzymatic action on fibrin, the protein responsible for forming the meshwork of blood clots.

Improvement of Microcirculation: By reducing the viscosity of the blood and preventing the accumulation of fibrin deposits in small vessels, the medication enhances blood flow to tissues and organs.
Reduction of Inflammation: The proteolytic enzymes in Trombovazim help break down inflammatory mediators, which can lead to a reduction in pain, redness, and swelling associated with vascular disorders.
Vascular Protection: The medication contributes to the integrity of the vascular endothelium, helping to maintain the health of the inner lining of blood vessels and preventing further complications from chronic vascular stasis.
High Bioavailability: The formulation is designed to ensure that the active enzymes reach the bloodstream effectively, allowing for consistent therapeutic action throughout the circulatory system.

Regulatory References

NIH National Library of Medicine

Eligibility and Restrictions for Use

The official regulatory documentation for Trombovazim defines population eligibility through specific contraindications and conditional use requirements, focusing its application on the adult population.

Eligibility Scope

Populations for whom use is contraindicated:

Patients with known hypersensitivity to the preparation or any excipients.
Women who are pregnant or lactating (breastfeeding).
Patients under 18 years of age, as efficacy and safety are not established in this group.
Patients with a gastric or duodenal ulcer when in the acute phase.

Condition-Specific Eligibility:

Use is permitted with caution in patients with a history of peptic ulcer in remission, chronic obstructive pulmonary disease (COPD), polyvalent allergy, urolithiasis (kidney stones), and those with a threat of bleeding from esophageal varices.

Eligibility-Related Restrictions:

The medicine must not be taken simultaneously with tetracycline antibiotics or any medications containing bivalent metal salts (such as iron, calcium, or magnesium), due to the risk of reducing the drug's activity.

What should I know about interactions with other medicines?

The official regulatory profile for Trombovazim describes two categories of clinically significant interactions with other substances and medicinal products. All documented interaction information is derived from official prescribing documents.

Pharmacodynamic Interactions

Co-administration of this medicine with other agents that affect blood coagulation or platelet function is documented to result in a pharmacodynamic reinforcement effect. This includes official cautions regarding the use of Trombovazim alongside anticoagulants, such as Warfarin and Heparin, as well as antiplatelet agents, including Aspirin and Clopidogrel. The regulatory status for these combinations notes an officially increased risk of bleeding due to the additive nature of their antithrombotic effects.

Exposure-Modifying Interactions and Administration Constraints

Trombovazim is officially contraindicated for co-administration with certain products due to the risk of altering its bioavailability and reducing its efficacy. These substances include tetracycline antibiotics and compounds containing divalent metal salts, such as supplements containing Calcium, Magnesium, Iron, or Zinc. The restriction against co-administration stems from the documented reduction in drug exposure. Consequently, the official labeling mandates a separation of administration timing for Trombovazim from these specific antibiotics and mineral salt products to mitigate the formal exposure-modifying outcome.

Mechanism of Action

How Trombovazim Works

The action of Trombovazim is based on a multi-domain influence targeting the processes of fibrinolysis, coagulation, and inflammation. The mechanism is driven by a recombinant enzyme that exerts distinct, yet complementary, effects at the molecular level.

Direct Enzymatic Degradation of Fibrin

This core mechanism involves a highly specific enzyme that targets the fibrin polymer, the main structural protein of clots. The enzyme directly degrades the fibrin meshwork into soluble fragments . This molecular step mediates the re-establishment of the physical patency of blood vessels, thereby facilitating the restoration of blood flow within the microvasculature.

Modulating Coagulation and Fibrin Generation

Beyond breaking down established fibrin structures, the enzyme also modulates the coagulation system. By interacting with the precursor protein fibrinogen, it restricts its potential conversion into new fibrin. This function limits the consolidation of existing fibrin structures and reduces the rate of new fibrin generation, which helps maintain the kinetic properties of the blood.

Anti-Inflammatory Cascade Modulation

A separate mechanistic domain involves the drug's influence on the inflammatory response. Trombovazim acts as a modulator of immune cell activity, regulating the infiltration and activation of leukocytes in localized areas. This mechanism reduces the intensity of the inflammatory response, resulting in a lower degree of inflammatory changes in the local tissue environment.

Dosage and Administration Information

Official Administration Guidelines

Trombovazim is a pharmaceutical agent formulated as capsules for oral administration. The proper use of the medicine is based on specific dosing, timing, and course duration.

Dosing and Frequency Schedule

Route: The medicine is to be taken perorally (by mouth).
Dosage: The standard daily dose is between 800 IU and 1600 IU, with a maximum daily dose of 2000 IU. The total daily amount must be divided into two doses (e.g., twice daily).
Strengths: Trombovazim capsules are available in different strengths, including 400 U, 600 U, and 800 U.

Administration Timing and Restrictions

Timing: Each dose must be taken 30 to 40 minutes before a meal.
Duration: A single course of treatment is defined as 20 days. Repeated courses are possible but require consultation with a physician.
Age Restriction: Use of Trombovazim is contraindicated for patients under 18 years of age, as safety and efficacy have not been established in this population.
Drug Interaction Constraint: Concurrent intake is forbidden with medicines containing divalent metal salts (such as calcium, iron, or magnesium) and tetracycline antibiotics. A minimum time interval of 40 minutes must be observed when using these agents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trombovazim

Evidence for use in Chronic Venous Insufficiency (CVI) and Symptom Management

The clinical evaluation of Trombovazim has primarily involved short-term to intermediate-term randomized controlled trials (RCTs). These studies were conducted to understand how Trombovazim was observed in adult populations with symptomatic Chronic Venous Insufficiency (CVI). The research examined patient-reported experiences related to physical discomfort, such as persistent leg heaviness, noticeable swelling (edema), pain, and cramps. The research explored how symptoms such as leg heaviness, pain, and swelling change over time.

These studies focused on measuring changes in patient-reported outcomes over defined time intervals, typically ranging from 60 days to 12 weeks. Findings describe patterns observed in the trials, reflecting how symptoms changed in the observed populations. Long-term effects are not fully established, as follow-up durations were limited.

Evidence for use in Deep Vein Thrombosis (DVT)

Research exploring the use of Trombovazim as an adjunctive treatment for acute Deep Vein Thrombosis (DVT) involved small-scale, randomized clinical trials (often at the pilot study level) alongside pre-clinical work. These studies focused on understanding the agent's role in research exploring temporary physiological imbalance.

Research monitored the frequency of clot dissolution and the restoration of blood flow (vessel recanalization) over a short, defined treatment period, typically around 10 to 12 days. Data show patterns related to these objective measures of changes in clot structures. Sample sizes were modest in the pivotal human studies, meaning results apply only to the populations studied and are not broadly generalizable across all groups.

Long-term Follow-up and Unaddressed Areas

The available research focuses predominantly on short-term to intermediate-term effects. The evidence does not clearly characterize sustained patterns or the prevention of symptom recurrence over many years. This significant gap is the lack of detailed long-term outcomes data. Data for certain groups, such as specific disease severity subgroups or individuals with certain comorbid conditions, also remain insufficient. Research is ongoing to further explore these areas.

Frequently Asked Questions (FAQ)

Common questions about Trombovazim (FAQ)

Q: Can I use Trombovazim for prevention of blood clots, or is it only for treatment?

According to the official product information, Trombovazim is indicated as an adjunctive medicine in the complex therapy for conditions like chronic venous insufficiency. The regulatory documents primarily describe its use in the treatment of established conditions and do not list the prevention of blood clots (prophylaxis) as an official indication.

Q: What are the most common side effects I should be aware of?

Official regulatory documents do not use the specific phrase 'most common' to describe side effect frequency. The prescribing information lists certain gastrointestinal effects, such as nausea, vomiting, or a sense of heaviness in the stomach, as 'Occasional / In Rare Cases.' Allergic reactions are listed as 'Possible.' Information regarding side effects is located in the official prescribing information, which categorizes frequencies as 'Occasional / In Rare Cases' or 'Possible.'

Q: How long does it take for Trombovazim to start working after I begin treatment?

Official pharmacological data indicates that the maximum concentration of the medicine in the body is observed approximately 6 hours after a dose is taken. This time frame describes the peak concentration of the substance, which is a pharmacological measure and is distinct from the time it may take to observe therapeutic results.

Q: What should I do with expired or unused Trombovazim capsules?

The official disposal requirements state that unused or expired Trombovazim must be handled according to local protocols for pharmaceutical waste. The product should not be disposed of in household trash or wastewater. For specific disposal instructions, patients may refer to guidance provided by their local municipality or pharmacy.

How should Trombovazim be stored and disposed of?

The storage and disposal of Trombovazim capsules must strictly follow the conditions specified in the official regulatory labeling.

Official Storage Conditions

To ensure the stability of the proteolytic enzyme preparation, Trombovazim must be stored within strict environmental limits.

Condition	Requirement
Temperature	Store below 25 C (77°F).
Protection	Keep in a dry place and protected from light.
Child Safety	Must be stored out of the sight and reach of children.
Stability	The medicine has a labeled shelf-life of three years when stored correctly.